2 results
Approved WMORecruiting
To evaluate, in patients with end stage knee osteoarthritis, the in vivo disease (tissue structure) modifying activity of celecoxib, as a selective COX-2 inhibitor, in addition to its inflammation regulatory properties, compared to naproxen as a…
Approved WMORecruiting
Zie pagina 39-40 van het protocol MO22923 versie 2, 26 Mei 2011